CRSP insider buying – CRISPR Therapeutics AG
12 insider purchases since 2016 worth $84.9M by 11 different insiders. Last 12 months: 1 purchases, $49,704. Most recent filing: 2026-01-27.
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits. 8 older purchases (before the 5-year window) are listed in the table below.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| George Simeon Director | $51.5M 1× · 989,812 sh | 2025-07-16 2025-07-16 | – | 2,038,763 shares as of 2025-07-17 | Holds - never sold |
| BAYER AKTIENGESELLSCHAFT 10% Owner | $12.0M 1× · 527,472 sh | 2018-01-05 2018-01-05 | – | 5,632,802 shares as of 2018-01-30 | Holds - never sold |
| CELGENE CORP /DE/ 10% Owner | $11.2M 1× · 800,150 sh | 2016-10-24 2016-10-24 | 1× · $21.1M last 2017-11-03 | 4,568,019 shares as of 2017-12-07 | Sold part |
| EMSTER KURT VON Director | $2.3M 2× · 121,934 sh | 2016-10-24 2018-01-05 | 21× · $52.7M last 2018-12-17 | 1,171,268 shares as of 2019-01-18 | Sold part |
| Bolzon Bradley J PhD Director | $2.3M 1× · 161,000 sh | 2016-10-24 2016-10-24 | 22× · $106.6M last 2021-07-19 | 149,531 shares as of 2021-07-21 | Sold part |
| Vertex Pharmaceuticals (Europe) Ltd 10% Owner | $2.2M 1× · 90,742 sh | 2018-12-21 2018-12-21 | – | 5,275,345 shares as of 2018-12-26 | Holds - never sold |
| Treco Douglas A Director | $1.1M 1× · 20,000 sh | 2025-08-06 2025-08-06 | – | 22,000 shares as of 2025-08-08 | Holds - never sold |
| VERTEX PHARMACEUTICALS INC / MA 10% Owner | $1.0M 1× · 40,198 sh | 2018-12-26 2018-12-26 | – | 5,380,940 shares as of 2018-12-28 | Holds - never sold |
| GLAXOSMITHKLINE PLC 10% Owner | $931,000 1× · 66,500 sh | 2016-10-24 2016-10-24 | – | 2,942,560 shares as of 2016-10-26 | Holds - never sold |
| Greene John Director | $313,950 1× · 7,000 sh | 2025-02-26 2025-02-26 | – | 7,000 shares as of 2025-02-28 | Holds - never sold |
| Patel Naimish Officer | $49,704 1× · 1,508 sh | 2025-04-03 2025-04-03 | 3× · $503,912 last 2026-05-29 | 23,143 shares as of 2026-06-01 | Sold part |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 1 | $49,704 | 1 | 17 | $13.9M |
| 2025 | 3 | $53.0M | 3 | 17 | $9.6M |
| 2024 | 0 | – | – | 15 | $13.8M |
| 2023 | 0 | – | – | 5 | $6.5M |
| 2022 | 0 | – | – | 7 | $10.5M |
| 2021 | 0 | – | – | 16 | $94.3M |
| 2020 | 0 | – | – | 29 | $100.2M |
| 2019 | 0 | – | – | 14 | $22.6M |
| 2018 | 4 | $16.7M | 4 | 17 | $84.6M |
| 2017 | 1 | $784,000 | 1 | 39 | $41.2M |
| 2016 | 3 | $14.4M | 3 | – | – |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2026-01-27 | Patel Naimish | Officer | 1,508 | $32.96 | $49,704 | SEC | |
| 2025-08-08 | Treco Douglas A | Director | 20,000 | $57.03 | $1.1M | +1000.0% | SEC |
| 2025-07-17 | George Simeon | Director | 989,812 | $52.03 | $51.5M | +133.7% | SEC |
| 2025-02-28 | Greene John | Director | 7,000 | $44.85 | $313,950 | SEC | |
| 2018-12-28 | VERTEX PHARMACEUTICALS INC / MA | 10% Owner | 40,198 | $24.93 | $1.0M | +0.8% | SEC |
| 2018-12-26 | Vertex Pharmaceuticals (Europe) Ltd | 10% Owner | 90,742 | $24.08 | $2.2M | +1.7% | SEC |
| 2018-01-30 | BAYER AKTIENGESELLSCHAFT | 10% Owner | 527,472 | $22.75 | $12.0M | +10.3% | SEC |
| 2018-01-11 | EMSTER KURT VON | Director | 65,934 | $22.75 | $1.5M | +3.6% | SEC |
| 2017-02-10 | EMSTER KURT VON | Director | 56,000 | $14.00 | $784,000 | +2.2% | SEC |
| 2016-12-23 | Bolzon Bradley J PhD | Director | 161,000 | $14.00 | $2.3M | +4.1% | SEC |
| 2016-10-26 | GLAXOSMITHKLINE PLC | 10% Owner | 66,500 | $14.00 | $931,000 | +2.1% | SEC |
| 2016-10-26 | CELGENE CORP /DE/ | 10% Owner | 800,150 | $14.00 | $11.2M | +19.8% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | KASINGER JAMES R. | Officer | 10,400 | $60.24 | $626,496 | Sale | SEC |
| 2026-09-21 | Behbahani Ali | Director | 13,679 | $57.09 | $780,934 | Sale | SEC |
| 2026-06-01 | Patel Naimish | Officer | 3,786 | $55.62 | $210,577 | Sale | SEC |
| 2026-03-24 | Prasad Raju | CFO | 3,708 | $46.78 | $173,460 | Sale | SEC |
| 2026-03-24 | Kulkarni Samarth | CEO | 10,020 | $46.78 | $468,736 | Sale | SEC |
| 2026-03-24 | KASINGER JAMES R. | Officer | 3,182 | $46.78 | $148,854 | Sale | SEC |
| 2026-03-17 | Prasad Raju | CFO | 9,869 | $48.26 | $476,278 | Sale | SEC |
| 2026-03-17 | Patel Naimish | Officer | 3,150 | $48.26 | $152,019 | Sale | SEC |
| 2026-03-17 | Kulkarni Samarth | CEO | 10,349 | $48.26 | $499,443 | Sale | SEC |
| 2026-03-17 | KASINGER JAMES R. | Officer | 3,450 | $48.26 | $166,497 | Sale | SEC |
| 2026-03-12 | Kulkarni Samarth | CEO | 9,798 | $52.80 | $517,334 | Sale | SEC |
| 2026-03-12 | KASINGER JAMES R. | Officer | 2,800 | $52.80 | $147,840 | Sale | SEC |
| 2026-02-20 | Kulkarni Samarth | CEO | 6,967 | $52.58 | $366,325 | Sale | SEC |
| 2026-02-20 | KASINGER JAMES R. | Officer | 2,112 | $52.58 | $111,049 | Sale | SEC |
| 2026-01-26 | Prasad Raju | CFO | 34,972 | $60.19 | $2.1M | Sale | SEC |
Showing the latest 15 of 176 sales of $50,000+ since 2016.
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free